目的 探讨醒脑静注射液联合依达拉奉注射液治疗重型颅脑损伤的临床疗效。方法 选取2017年2月-2019年3月武汉科技大学附属普仁医院收治的73例重型颅脑损伤患者，将所有患者按照不同的治疗方式分为对照组（36例）和治疗组（37例）。对照组静脉滴注依达拉奉注射液，30 mL依达拉奉注射液加入100 mL氯化钠注射液内，2次/d。治疗组在对照组治疗基础上静脉滴注醒脑静注射液，20 mL/次，2次/d。两组患者均连续治疗2周。观察两组的临床疗效，比较两组的平均血流速度（V_m）、收缩血流速度（V_s）水平、残余血肿量、水肿范围以及血清脑血红蛋白水平变化。结果 治疗后，对照组总有效率83.3%低于治疗组总有效率94.6%（P<0.05）。经治疗后，两组患者V_m、V_s水平均显著升高（P<0.05），且治疗组V_m、V_s提高程度优于对照组（P<0.05）。经治疗后，两组患者水肿范围、残余血肿量与治疗前相比均降低（P<0.05），且治疗组水肿范围、残余血肿量改善程度优于对照组（P<0.05）。治疗后，两组血清脑血红蛋白水平均显著提高（P<0.05），且治疗组血清脑血红蛋白水平高于对照组（P<0.05）。结论 醒脑静注射液联合依达拉奉注射液治疗重型颅脑损伤具有较好的疗效，可提高患者V_m、V_s水平，降低水肿范围和残余血肿量，具有一定的临床应用推广价值。

Objective To evaluate the efficacy of Xingnaojing Injection combined with Edaravone Injection in the treatment of severe craniocerebral injury. Methods Patients (73 cases) with severe craniocerebral injury in Wuhan Puren Hospital Affiliated to Wuhan University of Science and Technology from February 2017 to March 2019 were enrolled in this study. According to the difference treatment plan, patients were randomly divided into the control group (36 cases) and the treatment group (37 cases). Patients in the control group were iv administered with Edaravone Injection, 30 mL added into normal saline 100 mL, twice daily. Patients in the treatment group were iv administered with Xingnaojing Injection on the basis of the control group, 20 mL/time, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and V_m, V_s, residual hematoma volume, edema range, and cerebral hemoglobin in two groups were compared. Results After treatment, the total effective rate of the control group was 83.3%, which was lower than 94.6% of the treatment group (P<0.05). After treatment, the levels of V_m and V_s in two groups were significantly increased (P<0.05), and the improvement of V_m and V_s in the treatment group was better than that in the control group (P<0.05). After treatment, the edema scope and residual hematoma volume of two groups were decreased (P<0.05), and the improvement degree of the treatment group was better than that of the control group (P<0.05). After treatment, the serum levels of brain hemoglobin in two groups were significantly increased (P<0.05), and the serum level of brain hemoglobin in the treatment group was higher than that of the control group (P<0.05). Conclusion Xingnaojing Injection combined with Edaravone Injection has a significant therapeutic effect in treatment of severe craniocerebral injury, can improve the level of V_m and V_s, reduce the range of edemaand the amount of residual hematoma, which has a certain clinical application value.

R971